Zacks Investment Research
02 Sept 2026, 14:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
The loss of exclusivity for Stelara reduced the growth of J&J's Innovative Medicines segment by 10.4% in 2025 and 8.4% in the first half of 2026. — A significant drag on a primary revenue driver directly impacts top-line growth and profit margins.
-0.80Johnson & Johnson expects generic competition for Simponi and Opsumit to weigh on sales throughout 2026. — Continued patent expirations create a compounding negative effect on the pharmaceutical pipeline's value.
-0.60Sales in J&J's Abiomed business declined 2% in Q2 due to slowing procedure volumes following a U.K. clinical trial that questioned the device's benefit. — Clinical trial concerns can lead to long-term utilization drops and regulatory scrutiny for MedTech products.
-0.40Continue reading
6 related stories
Top 1 mover · tap to explore
J&J continues to face investor concerns regarding lingering talc-related litigation and pricing pressure in key markets. — Ongoing legal liabilities create a persistent risk overhang and uncertainty for the stock's valuation.
-0.30Which stocks this story touches
The company faces headwinds from major patent expirations for Stelara, pricing pressure, and ongoing talc-related litigation.
The company is benefiting from the launch of a biosimilar version of J&J's Stelara.
The company is benefiting from the launch of a biosimilar version of J&J's Stelara.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Reuters
5h ago
